Parkinson DiseaseEPMP-1NCT02824367
Evaluation of Clinical Perfectionism in Parkinson Disease
A study testing Completion of scales evaluation in people with Parkinson Disease, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
Trial summary
Scientific studies show that almost half of the people with Parkinson's Disease (PD) suffer of depression and / or anxiety. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Parkinson Disease
- What is being tested?
- Completion of scales evaluation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 59 participants
- Where
- 1 siteFrance
- Study dates
- 6 Oct 2014to 25 Aug 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age greater than 18 years
- Score Mini Mental Scale (MMS) greater than 23
- For Parkinsonian, Parkinson disease be defined according to the criteria of the Unified Parkinson Disease Rating Scale (UPDRS), with a Hoehn and Yahr stage 1, 2 or 3
- The control patients present dystonias not within the scope of Parkinson
- Informed Consent Form signed
- Patient covered by social insurance
Who cannot join
- Proven Presence of neuropsychological disorders
- Patients with deep brain stimulation
- Diagnosis of somatic pathology diagnosed
- Private Patient freedom or protected adult (under guardianship)
Trial locations and contacts
1 site in 1 country.
About this study
Scientific studies show that almost half of the people with Parkinson's Disease (PD) suffer of depression and / or anxiety.
Read the detailed description
Scientific studies show that almost half of the people with Parkinson's Disease (PD) suffer of depression and / or anxiety. Also, clinicians reported that they exhibit specific personality traits (e.g., rigidity and perfectionism).
To date, few studies used Cognitive Behavioural Therapies (CBT) in people with Parkinson's disease showing promising results. Recently, perfectionism has received particular attention because of it association with many emotional disorders. Thus, some psychometric tools have been developed in order to evaluate different aspects of perfectionism. Yet, none of them has been used in people with Parkinson's disease.
The objective of this study is to investigate whether there is a direct link between Parkinson's disease and perfectionism by using psychometric tools from the CBT literature. Identifying such link would allow to justify the use of CBT in people with Parkinson's disease with the goal in mind to improve their care and quality of life.
- Conditions
- Parkinson Disease
- Being tested
- Completion of scales evaluation
- Keywords
- Parkinson, Perfectionism
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Completion of scales evaluationBehavioural
Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))
| Study group | Role | What they receive |
|---|---|---|
| Parkinsonian | Other | Patient Arm: Parkinsonian will complete several scale of evaluation. Behavioral: Completion of scales evaluation Receives: Behavioral: Completion of scales evaluation |
| Dystonic | Other | Comparator Arm: Dystonic patient will complete several scale of evaluation. Behavioral: Completion of scales evaluation Receives: Behavioral: Completion of scales evaluation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Perfectionism evaluation 1
Scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS)
Measured: Day 0
Perfectionism evaluation 2
Hewitt Multidimensional Perfectionism Scale (HMPS).
Measured: Day 0
Secondary outcomes (2)
Depression and anxiety evaluation 1
Scores to depression scale (Beck Depression Inventory (BDI))
Measured: Day 0
Depression and anxiety evaluation 2
anxiety scale (State Trait Anxiety Inventory (STAI))
Measured: Day 0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2016 (estimated)
- Study start6 Oct 2014
- Primary completion25 Aug 2017
- Study completion25 Aug 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire, AmiensThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Enrolment
- 59 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Pierre KRYSTKOWIAK, MD, PhD, Principal investigator, CHU Amiens
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02824367
- Sponsor's protocol ID
- PI2014_843_0002
- Other IDs
- 2013-A01302-43
- Acronym
- EPMP-1
- Status last verified
- Jun 2026
- First submitted
- 22 Apr 2014
- Last updated
- 12 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Clinical Perfectionism in Parkinson Disease
- ClinicalTrials.gov ID
- NCT02824367
- Acronym / sponsor ID
- EPMP-1 / PI2014_843_0002
- Conditions
- Parkinson Disease
- Keywords
- Parkinson, Perfectionism
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 59 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire, AmiensUniversity, hospital or other
- Study start
- 6 Oct 2014 (actual)
- Primary completion
- 25 Aug 2017 (actual)
- Study completion
- 25 Aug 2017 (actual)
- First posted
- 6 Jul 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Scientific studies show that almost half of the people with Parkinson's Disease (PD) suffer of depression and / or anxiety.
Detailed description
Scientific studies show that almost half of the people with Parkinson's Disease (PD) suffer of depression and / or anxiety. Also, clinicians reported that they exhibit specific personality traits (e.g., rigidity and perfectionism).
To date, few studies used Cognitive Behavioural Therapies (CBT) in people with Parkinson's disease showing promising results. Recently, perfectionism has received particular attention because of it association with many emotional disorders. Thus, some psychometric tools have been developed in order to evaluate different aspects of perfectionism. Yet, none of them has been used in people with Parkinson's disease.
The objective of this study is to investigate whether there is a direct link between Parkinson's disease and perfectionism by using psychometric tools from the CBT literature. Identifying such link would allow to justify the use of CBT in people with Parkinson's disease with the goal in mind to improve their care and quality of life.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Parkinsonian | Other | Behavioral: Completion of scales evaluationPatient Arm: Parkinsonian will complete several scale of evaluation. Behavioral: Completion of scales evaluation |
| Dystonic | Other | Behavioral: Completion of scales evaluationComparator Arm: Dystonic patient will complete several scale of evaluation. Behavioral: Completion of scales evaluation |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age greater than 18 years
- Score Mini Mental Scale (MMS) greater than 23
- For Parkinsonian, Parkinson disease be defined according to the criteria of the Unified Parkinson Disease Rating Scale (UPDRS), with a Hoehn and Yahr stage 1, 2 or 3
- The control patients present dystonias not within the scope of Parkinson
- Informed Consent Form signed
Key exclusion criteria (4 listed)
- Proven Presence of neuropsychological disorders
- Patients with deep brain stimulation
- Diagnosis of somatic pathology diagnosed
- Private Patient freedom or protected adult (under guardianship)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Completion of scales evaluationPatient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI)) | Behavioural | Dystonic, Parkinsonian |
Primary outcome
Perfectionism evaluation 1
Time frame: Day 0
Scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS)
Perfectionism evaluation 2
Time frame: Day 0
Hewitt Multidimensional Perfectionism Scale (HMPS).
2 secondary outcomes
Depression and anxiety evaluation 1
Time frame: Day 0
Depression and anxiety evaluation 2
Time frame: Day 0
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2026.
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pierre KRYSTKOWIAK, MD, PhD principal investigator
CHU Amiens
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Completion of scales evaluation in people with Parkinson Disease, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Perfectionism evaluation 1 (time frame: Day 0). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2026.